n(g),n(g')-dimethyl-l-arginine has been researched along with Hyperlipemia in 14 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
| Excerpt | Relevance | Reference |
|---|---|---|
| "BET supplementation may be effective in preventing hyperlipidemia, disturbed NO availability, oxidative stress, and the development of fatty liver and atherosclerotic lesions that might result from excess amounts of cholesterol and methionine in the diet." | 7.88 | Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. ( Bekpınar, S; Çevik, A; Genc, S; Gürdöl, F; Küskü-Kiraz, Z; Olgaç, V; Ünlücerci, Y; Uysal, M, 2018) |
| "Global L-arginine bioavailability was diminished, whereas plasma arginase activity, ADMA, and SDMA levels were elevated, in patients with RA compared with healthy control subjects." | 5.48 | Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. ( Chandrasekharan, UM; Elaine Husni, M; Hazen, SL; Wang, S; Wang, Z; Wilson Tang, WH; Wu, Y, 2018) |
| " A total of 83 patients with hypercholesterolemia and angiographically documented mild coronary artery stenosis were randomized to rosuvastatin treatment (20 mg) or atorvastatin treatment (40 mg) once daily for 6 weeks after a 4-week dietary lead-in phase." | 5.19 | Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease. ( Akturk, E; Altas, Y; Atas, H; Balta, S; Can, C; Demirkol, S; Erdem, K; Korkmaz, H; Kurtoglu, E; Sincer, I; Yilmaz, M, 2014) |
| " Thus, together with classic risk factors such as hypertension, dyslipidemia and diabetes, other situations such as microinflammation, increased concentration of asymmetrical dimethyl-L-arginine, disturbed phosphate metabolism and anemia may represent important risk factors for accelerated atherosclerosis in dialyzed patients." | 4.82 | Atherosclerosis in dialyzed patients. ( Ritz, E, 2004) |
| "BET supplementation may be effective in preventing hyperlipidemia, disturbed NO availability, oxidative stress, and the development of fatty liver and atherosclerotic lesions that might result from excess amounts of cholesterol and methionine in the diet." | 3.88 | Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet. ( Bekpınar, S; Çevik, A; Genc, S; Gürdöl, F; Küskü-Kiraz, Z; Olgaç, V; Ünlücerci, Y; Uysal, M, 2018) |
| "Treatment with fenofibrate did not alter plasma ADMA level, in contrast to serum triglycerides which were significantly lowered and plasma total homocysteine which was significantly increased." | 2.71 | Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. ( Bode-Böger, SM; Dierkes, J; Luley, C; Martens-Lobenhoffer, J; Westphal, S, 2004) |
| "Global L-arginine bioavailability was diminished, whereas plasma arginase activity, ADMA, and SDMA levels were elevated, in patients with RA compared with healthy control subjects." | 1.48 | Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. ( Chandrasekharan, UM; Elaine Husni, M; Hazen, SL; Wang, S; Wang, Z; Wilson Tang, WH; Wu, Y, 2018) |
| "Captopril treatment not only decreased vascular intima thickening and serum ADMA concentration but also preserved vascular DDAH activity and endothelium-dependent relaxation in hyperlipidemic rabbits without influence on serum lipid profiles." | 1.46 | Preservation of vascular DDAH activity contributes to the protection of captopril against endothelial dysfunction in hyperlipidemic rabbits. ( Feng, M; He, ZM; Lei, YP; Lin, Y; Lu, CW; Xiong, Y, 2017) |
| "In the multivariate analysis dyslipidemia, left ventricular hypertrophy, age and LDL-c (negatively) were associated with CVD." | 1.36 | [Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors]. ( Azqueta, M; Cases, A; Coll, E; Collado, S; Cruzado, JM; de la Torre, B; Deulofeu, R; Guerrero, L; Nicolau, C; Pons, M; Vera, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CH | 1 |
| Zhao, JF | 1 |
| Hsu, CP | 1 |
| Kou, YR | 1 |
| Lu, TM | 1 |
| Lee, TS | 1 |
| Szentpéteri, A | 1 |
| Zsíros, N | 1 |
| Varga, VE | 1 |
| Lőrincz, H | 1 |
| Katkó, M | 1 |
| Seres, I | 1 |
| Fülöp, P | 1 |
| Paragh, G | 1 |
| Harangi, M | 1 |
| Küskü-Kiraz, Z | 1 |
| Genc, S | 1 |
| Bekpınar, S | 1 |
| Ünlücerci, Y | 1 |
| Çevik, A | 1 |
| Olgaç, V | 1 |
| Gürdöl, F | 1 |
| Uysal, M | 1 |
| Chandrasekharan, UM | 1 |
| Wang, Z | 1 |
| Wu, Y | 1 |
| Wilson Tang, WH | 1 |
| Hazen, SL | 1 |
| Wang, S | 1 |
| Elaine Husni, M | 1 |
| Kasapkara, ÇS | 1 |
| Tümer, L | 1 |
| Biberoglu, G | 1 |
| Kasapkara, A | 1 |
| Hasanoğlu, A | 1 |
| Kurtoglu, E | 1 |
| Balta, S | 1 |
| Sincer, I | 1 |
| Altas, Y | 1 |
| Atas, H | 1 |
| Yilmaz, M | 1 |
| Korkmaz, H | 1 |
| Erdem, K | 1 |
| Akturk, E | 1 |
| Demirkol, S | 1 |
| Can, C | 1 |
| Lin, Y | 1 |
| Feng, M | 1 |
| Lu, CW | 1 |
| Lei, YP | 1 |
| He, ZM | 1 |
| Xiong, Y | 2 |
| Durmus, N | 1 |
| Toylu, A | 1 |
| Evcim, S | 1 |
| Soner, BC | 1 |
| Demir, O | 1 |
| Kahraman, E | 1 |
| Demir, T | 1 |
| Irer, B | 1 |
| Gidener, S | 1 |
| Atabey, N | 1 |
| Esen, A | 1 |
| Collado, S | 1 |
| Coll, E | 1 |
| Deulofeu, R | 1 |
| Guerrero, L | 1 |
| Pons, M | 1 |
| Cruzado, JM | 1 |
| de la Torre, B | 1 |
| Vera, M | 1 |
| Azqueta, M | 1 |
| Nicolau, C | 1 |
| Cases, A | 1 |
| Zoccali, C | 1 |
| Böger, RH | 1 |
| Vallance, P | 1 |
| Cooke, JP | 1 |
| Ritz, E | 1 |
| Dierkes, J | 1 |
| Westphal, S | 1 |
| Martens-Lobenhoffer, J | 1 |
| Luley, C | 1 |
| Bode-Böger, SM | 1 |
| Li, YJ | 1 |
| Yu, XJ | 1 |
| Liu, GZ | 1 |
| Li, NS | 1 |
2 reviews available for n(g),n(g')-dimethyl-l-arginine and Hyperlipemia
| Article | Year |
|---|---|
[Cardiovascular events in chronic advanced renal insufficiency. Current concepts].
Topics: Anemia; Arginine; C-Reactive Protein; Cardiovascular Diseases; Humans; Hyperhomocysteinemia; Hyperli | 2003 |
Atherosclerosis in dialyzed patients.
Topics: Anemia; Animals; Arginine; Arteriosclerosis; Biomarkers; Cause of Death; Comorbidity; Coronary Arter | 2004 |
2 trials available for n(g),n(g')-dimethyl-l-arginine and Hyperlipemia
| Article | Year |
|---|---|
Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.
Topics: Arginine; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Stenosis; Down-Regulation; Female | 2014 |
Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration.
Topics: Adult; Arginine; Biomarkers; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Meth | 2004 |
10 other studies available for n(g),n(g')-dimethyl-l-arginine and Hyperlipemia
| Article | Year |
|---|---|
The detrimental effect of asymmetric dimethylarginine on cholesterol efflux of macrophage foam cells: Role of the NOX/ROS signaling.
Topics: Amidohydrolases; Animals; Arginine; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transpo | 2019 |
Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers in overweight patients with newly diagnosed untreated hyperlipidaemia.
Topics: Adult; Aged; Arginine; Aryldialkylphosphatase; Biomarkers; C-Reactive Protein; Case-Control Studies; | 2017 |
Effects of betaine supplementation on nitric oxide metabolism, atherosclerotic parameters, and fatty liver in guinea pigs fed a high cholesterol plus methionine diet.
Topics: Animals; Arginine; Atherosclerosis; Betaine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Diet | 2018 |
Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.
Topics: Aged; Arginase; Arginine; Arthritis, Rheumatoid; Biomarkers; Cardiovascular Diseases; Comorbidity; F | 2018 |
Asymmetric dimethylarginine (ADMA) and L-arginine levels in children with glycogen storage disease type I.
Topics: Adolescent; Arginine; Child; Child, Preschool; Fatty Acids; Female; Glycogen Storage Disease Type I; | 2013 |
Preservation of vascular DDAH activity contributes to the protection of captopril against endothelial dysfunction in hyperlipidemic rabbits.
Topics: Amidohydrolases; Animals; Arginine; Captopril; Diet, High-Fat; Endothelium, Vascular; Enzyme Inhibit | 2017 |
Time-course changes of nLDL-induced erectile dysfunction.
Topics: Animals; Arginine; Disease Models, Animal; Endothelium, Vascular; Erectile Dysfunction; Hyperlipidem | 2017 |
[Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors].
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Blood Proteins; Cardiovascular Diseases; Comorbidity; | 2010 |
Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase.
Topics: Arginine; Cardiovascular Diseases; Endothelium, Vascular; Enzyme Inhibitors; Homeostasis; Humans; Hy | 2003 |
Endogenous inhibitors of nitric oxide synthesis and lipid peroxidation in hyperlipidemic rabbits.
Topics: Animals; Aorta, Thoracic; Arginine; Hyperlipidemias; Lipid Peroxidation; Male; Malondialdehyde; Nitr | 1996 |